Why Cogent Biosciences, Inc. (COGT) stock moved
Cogent Biosciences, Inc. (COGT) shares tumbled 5.7% to $31.64 as of November 10, 2026, a significant decline from the prior close of $33.54. BestStocks flagged the session as a major change for COGT. The move is tied to price move down. Below, we break down what changed for COGT, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
COGT fell 5.7% to $31.64
Cogent Biosciences, Inc. (COGT) moved -5.44% from $33.46 to $31.64 on 2026-11-10. The decline followed the company's November 5 Q3 earnings report, which posted a net loss of $111.4 million (-$0.59 EPS) that missed consensus estimates of -$0.56 EPS by 5.4%, and CEO commentary at the Guggenheim Healthcare Innovation Conference on November 10 reiterating that the company is days away from potential FDA decisions on its lead drug bezuclastinib. Elevated general and administrative expenses ($42.1 million) tied to commercial readiness and profit-taking ahead of regulatory catalysts contributed to the weakness. FDA decision on bezuclastinib and Cogent's next earnings report scheduled for 2027-02-16 (consensus EPS estimate -$0.60).
What it means for Cogent Biosciences, Inc. investors
For Cogent Biosciences, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum; Cogent Biosciences, Inc. (COGT) moved +7.96% from $39.68 to $42.84 on 2026-08-04, reaching a new 30-day high on volume 3.3x the 5-day average. Weighing against that: Material negative event; Sharp 5.7% decline — elevated risk. Wall Street's consensus price target sits at $50.67, implying +60.1% upside from $31.64. BestStocks rates the overall signal quality medium (62/100). With earnings roughly 98 days out, the next report is the most likely near-term test of the move.
COGT price reaction
COGT last traded at $31.64, down $1.90 (-5.66%) from the previous close of $33.54. The session traded on 1.4× average volume (normal), so participation was unremarkable.
Bullish and bearish analyst opinions on Cogent Biosciences, Inc. (COGT)
The consensus analyst price target on Cogent Biosciences, Inc. (COGT) is $50.67, 60.1% above the recent $31.64. Over the past 90 days analysts logged 0 upgrades, 5 maintains, and 0 downgrades. Here is how the bullish and bearish cases on COGT line up.
The bullish case
- Wall Street's consensus price target of $50.67 implies +60.1% upside from $31.64.
- The Street's most bullish target is $55.00 (+73.8%).
- Positive price momentum.
- Cogent Biosciences, Inc. (COGT) moved +7.96% from $39.68 to $42.84 on 2026-08-04, reaching a new 30-day high on volume 3.3x the 5-day average.
The bearish case
- Material negative event.
- Sharp 5.7% decline — elevated risk.
- Cogent Biosciences filed a material event (8-K) and earnings report today, triggering a 6.12% intraday decline to $38.99.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 10, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for COGT
Frequently asked questions about COGT
Why did Cogent Biosciences, Inc. (COGT) stock move?
COGT tumbled 5.7% to $31.64. The move is associated with price move down.
How much did COGT stock fall?
COGT lost 5.66% ($1.90) versus the prior close of $33.54, last trading at $31.64 on 1.4× average volume.
When is Cogent Biosciences, Inc.'s next earnings date?
COGT's next earnings report is estimated for 2027-02-16 — about 98 days away.
What is the analyst price target for COGT?
The consensus analyst price target for COGT is $50.67, about 60.1% above the current $31.64. Over the past 90 days, analysts recorded 0 upgrades, 5 maintains, and 0 downgrades.
How BestStocks tracks COGT
This page is generated automatically by BestStocks' change-detection system after price move down was detected and verified against independent data sources. It draws on 20 tracked change events for COGT, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 10, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.